{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:40:02Z","timestamp":1781271602397,"version":"3.54.1"},"reference-count":14,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Aim: To investigate the effectiveness of rifaximin and probiotics for the correction of intestinal permeability in patients with metabolic-associated fatty liver disease (MAFLD) in combination with type 2 diabetes mellitus.\nMaterials and Methods: The prospective interventional randomized investigation included 68 patients with MAFLD in combination with type 2 diabetes, who were examined and divided into the 2 groups of treatment.\nResults: The serum levels of interleukin (IL) - 6, IL-10 and zonulin, indicators of liver functional activity, liver attenuation coefficient between treatment group vs. control group after 2 weeks, 1 month, 3 and 6 months of therapy were significant differed. The serum levels of IL-6 and zonulin significantly decreasing and increasing of IL-10 in the treatment group after 2 weeks, 1, 3 and 6 months of combined therapy. When comparing of stool short-chain fatty acids concentration between treatment group vs. control group after 2 weeks, 1 month, 3 and 6 months of therapy the levels of acetic, butyric and propionic acids significantly differences and increase in their levels were established.\nConclusions: The results of the study in dynamics during 6 months show that the additional appointment of rifaximin, multispecies probiotic and prebiotic to metformin in patients with MAFLD and type 2 diabetes led to the elimination of subclinical inflammation, modulation of the permeability of the intestinal barrier and lowering increased intestinal permeability, as well as to the lower serum activity of liver aminotransferases and decrease the stage of steatosis.<\/jats:p>","DOI":"10.36740\/wlek202404118","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:21:16Z","timestamp":1718306476000},"page":"732-738","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness of rifaximin and probiotics for the correction of intestinal permeability in patients with metabolic-associated fatty liver disease in combination with type 2 diabetes mellitus"],"prefix":"10.36740","volume":"77","author":[{"given":"Olga K.","family":"Didyk","sequence":"first","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volodymyr V.","family":"Chernyavskyi","sequence":"additional","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadym P.","family":"Shypulin","sequence":"additional","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoriia V.","family":"Tishchenko","sequence":"additional","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.Gastroenterology. 2020;158(7):1999-2014. doi:10.1053\/j.gastro.2019.11.312.","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Cui Y, Wang Q, Chang R et al. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota. J Agric Food Chem. 2019;67(10):2754-2762. doi:10.1021\/acs.jafc.9b00080.","DOI":"10.1021\/acs.jafc.9b00080"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Barbara G, Barbaro MR, Fuschi D et al. Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. Front Nutr. 2021;8:718356. doi:10.3389\/fnut.2021.718356.","DOI":"10.3389\/fnut.2021.718356"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9:F1000 Faculty Rev-69. doi:0.12688\/f1000research.20510.1.","DOI":"10.12688\/f1000research.20510.1"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Maestri M, Santopaolo F, Pompili M et al. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies. Front Nutr. 2023;10:1110536. doi:10.3389\/fnut.2023.1110536.","DOI":"10.3389\/fnut.2023.1110536"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal Barrier in Human Health and Disease. Int J Environ Res Public Health. 2021;18(23):12836. doi:10.3390\/ijerph182312836.","DOI":"10.3390\/ijerph182312836"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. ElSayed NA, Aleppo G, Aroda VR et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023;46 (1):19-40. doi:10.2337\/dc23-S002.","DOI":"10.2337\/dc23-ad08"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Kitsugi K, Kawata K, Noritake H et al. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation. J Clin Med. 2023;12(6):2210. doi:10.3390\/jcm12062210.","DOI":"10.3390\/jcm12062210"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Mohamad Nor MH, Ayob N, Mokhtar NM et al. The Effect of Probiotics (MCPR BCMCR Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients. 2021;13(9):3192. doi:10.3390\/nu13093192.","DOI":"10.3390\/nu13093192"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Ponziani FR, Zocco MA, D\u2019Aversa F et al. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017;23(25):4491-4499. doi:10.3748\/wjg.v23.i25.4491.","DOI":"10.3748\/wjg.v23.i25.4491"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Ayob N, Muhammad Nawawi KN, Mohamad Nor MH et al. The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines. 2023;11(2):640. doi:10.3390\/biomedicines11020640.","DOI":"10.3390\/biomedicines11020640"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189-200. doi:10.1080\/19490976.2015.1134082.","DOI":"10.1080\/19490976.2015.1134082"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Ikeda T, Nishida A, Yamano M et al. Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases. Pharmacol Ther. 2022;239:108273. doi:10.1016\/j.pharmthera.2022.108273.","DOI":"10.1016\/j.pharmthera.2022.108273"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Nazzaro F, Fratianni F, Orlando P, Coppola R. Biochemical Traits, Survival and Biological Properties of the Probiotic Lactobacillus plantarum Grown in the Presence of Prebiotic Inulin and Pectin as Energy Source. Pharmaceuticals (Basel). 2012;5(5):481-492. doi:10.3390\/ph5050481.","DOI":"10.3390\/ph5050481"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T17:47:47Z","timestamp":1725558467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/dl\/i\/pdf\/607\/2c367ce7d2d51208eab3df9a9e8e5cd7\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202404118","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}